Close
Search
bg-country-switch
Key figures

The HARTMANN GROUP, an internationally leading medical device company.

HARTMANN at a glance

We have offices in over 30 countries around the world, but our products are available in around 100 countries through a network of distributors.

HARTMANN is a leading international manufacturer of medical and hygiene products.

In a world where health is becoming an increasingly important matter and is managed more professionally, we offer our customers simple and effective solutions for the benefit of the patients. This is expressed in our brand promise of “Going further for health”. Professional solutions for wound treatment, incontinence hygiene and infection prevention form the core of our portfolio.

In 2017, we employed 10,764 staff worldwide and generated sales of EUR 2,058 million.

The HARTMANN solutions

In line with internal management, the HARTMANN GROUP's business activities are reported on by business segments which are arranged by product range focus, i.e. Wound, Incontinence and Infection Management as well as Other Group Activities, primarily including the activities of the Group companies, KNEIPP, KOB, CMC and NOGE.

In our Wound Management segment, HARTMANN has, among other things, further improved its highly absorbent Zetuvit® Plus, which is intended for wounds with high levels of exudate, and the HydroClean® plus dressing. This was singled out for its innovative absorbing-rinsing-mechanism by the Journal of Wound Care as Most Innovative New Dressing 2017.

Share of total sales by business segment

HARTMANN: Share of total sales by business segment 2017

In the Incontinence Management segment we have launched the Skintegrity® System. Skintegrity® stands for the alliance of absorbent incontinence products and medical skin care under the MoliCare® trademark. This ensures the best-possible support for keeping the skin healthy in case of incontinence. It has gradually been possible to establish the MoliCare® Premium Elastic all-in-one incontinence brief as a convincing solution in incontinence care both for people affected and for healthcare personnel. On the one hand, the product offers increased comfort for the wearer while,on the other, for healthcare personnel this means savings in time and effort spent applying it. And frequently occurring conditions of their musculoskeletal system are thus avoided.

In the Infection Management segment, the primary focus remains on innovations in products for hand and surface disinfection. These are an integral part of a multimodal, holistic concept for the improvement of hand hygiene.

Other Group Activities comprises our activities in cosmetic cotton-wool products, first aid, Kneipp product lines and retail business.

Share of total sales by region

HARTMANN: Share of total sales by region 2017
in EUR million and percent (2017)

Shares of regions in total sales of the HARTMANN GROUP (in million euros and as a percentage; discrepancies due to rounding not adjusted).

We are present in over 30 countries with our own sales and manufacturing organisations, but our solutions are available in around 100 countries through a network of distributors. You can find our offices in a number of countries throughout Europe, but we are also present in America, Africa, Asia, and Oceania.

In Germany, the HARTMANN GROUP includes, among others, the companies BODE Chemie/Hamburg, Karl Otto Braun/Wolfstein, Sanimed/Ibbenbüren and Kneipp/Würzburg.

Performance indicators

With targeted investments in the future and holistic healthcare solutions, we were able to increase Group sales by 3.6% during the 2017 financial year to €2.06 billion. This means we are building on the growth rates of previous years.

At €138.2 million, EBIT has declined slightly over the previous year. Next to the one-off effect from the LINDOR acquisition, this is largely due to pricing pressure on the markets for medical and healthcare products, as well as higher regulatory spending. However, thanks to an improved financial outcome we have increased the consolidated net income by 4.0%. The dividend remains stable.

in EUR thousand 20162017Year-on-year
change
in %
Earnings
Sales revenues1,986,450
2,058,6283.6
Of which outside Germany in %65.866.51.1
Consolidated net income90,10093,7044.0
Net return on sales in % 4.54.60.4
Cost of materials868,065873,0640.6
Personnel expense510,422528,9893.6
EBIT DA210,818204,798-2.9
Return on EBIT DA in %10.69.9-6.1
depreciation/amortization on
tangible and intangible assets		71,71766,571-7.2
EBIT139,101138,227-0.6
Return on EBIT in %7.0
6.7-4.1
Cash-Flow157,357169,4387.7
Free-Cash-Flow91,603
-2,503-102.7
Balance Sheet
Balance Sheet total1,329,3391,431,9697.7
Non-current assets514,486
640,51524.5
Investments in tangible and
intangible assets 2		69,203
66,513-3.9
Current assets814,853791,454-2.9
Equity capital and reserves816,208854,8384.7
Equity/asset ratio in %61.459.7-2.8
Return on equity in %11.0
11.0-0.7
Net Financial Status101,955
71,679-29.7
Employees as at Dec. 31 1)10,37210.7643.8

1) Excl. staff on parental leave and PAUL HARTMANN AG Management Board members

2) Excluding investments from acquisitions like goodwill